Ranimil 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Millat pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- Usual dosage is 150 mg twice daily for 4 to 8 weeks
- 300 mg as a single daily dose at night for 4 to 8 weeks
- 150 mg twice daily for up to 8 weeks for reflux oesophagitis
- 300 mg at bed time for up to 8 weeks for reflux oesophagitis
- 150 mg 3 times daily for Zollinger-Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- 300 mg at bed time for up to 6 weeks for episodic dyspepsia
- 150 mg at night for maintenance
- 2-4 mg/kg twice daily for children with peptic ulcer
- 50 mg slow intravenous injection or intermittent intravenous infusion every six to eight hours for haemorrhage from stress ulceration
- Continued dosage in seriously ill patients until oral feeding commences
- 50 mg intramuscularly or by slow intravenous injection 45 to 60 minutes before induction of general anesthesia for patients at risk of developing aspiration syndrome
- 2 mg/kg to 4 mg/kg twice daily to a maximum of 300 mg ranitidine per day for the treatment of peptic ulcer in children
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Minimally inhibits hepatic metabolism of certain drugs. May alter absorption of pH-dependent drugs. May reduce bioavailability with antacids.
Contraindications
Hypersensitivity to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Crosses the placenta but no evidence of impaired fertility or harm to the foetus
- Lactation: Excreted in human breast milk
Precautions & Warnings
Reduced dosage for patients with impaired renal and hepatic function
Use in Special Populations
Clinical trial indicates similar ulcer healing rates in elderly patients
Overdose Effects
No particular problems expected. Symptomatic and supportive therapy recommended. Haemodialysis may be used if required.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- 50 mg diluted to a concentration ≤2.5 mg/mL for slow IV inj
- 50 mg diluted to a concentration ≤0.5 mg/mL for intermittent slow IV infusion
- 150 mg diluted in 250 mL for continuous IV infusion
- Dilution to a concentration of ≤2.5 mg/mL for patients with hypersecretory conditions
Storage Conditions
Store in a cool and dry place. Protect from light.